NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.

Cover of Molecular Imaging and Contrast Agent Database (MICAD)

Molecular Imaging and Contrast Agent Database (MICAD) [Internet].

Show details

124I-Anti-CD44v6 chimeric monoclonal antibody U36

124I-cMAb U36
, PhD
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD, vog.hin.mln.ibcn@dacim

Created: ; Last Update: November 19, 2007.

Chemical name:124I-Anti-CD44v6 chimeric monoclonal antibody U36
Abbreviated name:124I-cMAb U36, 124I-U36
Synonym:
Agent Category:Antibody
Target:CD44v6
Target Category:Antibody-antigen binding
Method of detection:PET
Source of signal:124I
Activation:No
Studies:
  • Checkbox In Vitro
  • Checkbox Rodents
Click on protein, nucleotide (RefSeq), and gene for more information about CD44.

Background

[PubMed]

Extracellular matrix (ECM) adhesion molecules consist of a complex network of fibronectins, collagens, chondroitins, laminins, glycoproteins, heparin sulfate, tenascins, and proteoglycans that surround connective tissue cells, and they are mainly secreted by fibroblasts, chondroblasts, and osteoblasts (1). Cell substrate adhesion molecules are considered essential regulators of cell migration, differentiation, and tissue integrity and remodeling. These molecules play a role in inflammation, but they also participate in the process of invasion and metastasis of malignant cells in the host tissue (2). Invasive tumor cells adhere to the ECM, which provides a matrix environment for permeation of tumor cells through the basal lamina and underlying interstitial stroma of the connective tissue. Overexpression of matrix metalloproteinases by tumor cells allows intravasation of tumor cells into the circulatory system after degrading the basement membrane and ECM (3).

The splice variant v6 of the cell membrane glycoprotein CD44 (CD44v6) is expressed in only a few normal epithelial tissues (e.g., thyroid and prostate gland). CD44 binds to ECM and is associated with cell adhesion, lymphocyte activation, and tumor cell metastasis (4, 5). Elevated levels of CD44v6 have been found in epithelial tumors associated with a poor prognosis for cancer patients (5). U36, an anti-CD44v6 chimeric (mouse/human) monoclonal antibody (cMAb), was found not bind to follicles or C cells from normal human thyroid (6). CD44v6 is generally highly expressed in thyroid carcinoma (7). 124I-cMAb U36 was developed for imaging of CD44v6 expression in thyroid carcinomas and other epithelial tumors (8, 9).

Synthesis

[PubMed]

cMAb U36 was labeled with sodium [124I]iodide by electrophilic radioiodination via the chloramine-T (8) or Iodogen method (9). 124I-cMAb U36 was purified by gel filtration. Both methods provided labeling yields of >70%. The radiochemical purity was >97%. No specific activity values were reported.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Fortin et al. (8) reported that high-affinity 125I-cMAb U36 binding sites (Bmax = 570,000 ± 30,000 sites/cell, Kd = 11 ± 2 nM) were found on the cell surfaces of KAT-4 human anaplastic thyroid carcinoma cells lacking the sodium iodide symporter. Furthermore, 20% of 125I-cMAb U36 accumulated in the cells after 24 h at 37°C. The accumulation was reduced to 1% by excess cMAb U36. The labeled cells retained 29% of radioactivity after incubation in tracer-free medium alone for another 24 h at 37°C. No free 125I could be detected in the incubation medium. Verel et al. (9) reported that the immunoreactivity of 124I-cMAb U36 was 91.1 ± 3.9%.

Animal Studies

Rodents

[PubMed]

Fortin et al. (8) performed biodistribution and scintigraphic studies of 124I-cMAb U36 in nude mice bearing KAT-4 tumors in the left flank and the right front leg. The organs with the highest accumulation of 124I-cMAb U36 (in percent injected dose per gram (% ID/g)) were the urinary bladder (13.1 ± 4.0), lung (7.0 ± 1.3), heart (5.2 ± 1.3), spleen (4.5 ± 1.4), liver (3.9 ± 0.5), and kidneys (3.8 ± 1.0) at 24 h after injection. 124I-cMAb U36 uptake in the flank tumors was 8.2 ± 3.6% ID/g, 13.7 ± 0.7% ID/g, 21.8 ± 2.8% ID/g, and 12.8 ± 5.2% ID/g at 4, 24, 48, and 72 h, respectively. The uptake values in the leg tumors were similar to those of the flank tumors. The radioactivity in the thyroid was <1% ID/g at all time points studied. 124I-cMAb U36 exhibited a high blood radioactivity (21.8% ID/g) at 4 h, which gradually decreased to 9.5% ID/g at 72 h. On the other hand, 124I-cMAb U36 exhibited a low accumulation in the stomach with 5.1% ID/g at 4 h and 1.0% ID/g at 72 h. Scintigraphic images were obtained in the tumor-bearing mice at 24, 48, and 72 h after 124I-cMAb U36 injection. The tumors were clearly visible at all time points with the highest uptakes at 48 h. No blocking experiment was performed.

Verel et al. (9) performed biodistribution and scintigraphic studies in nude mice bearing tumors from the HNX-OE human head and neck tumor cell line. Co-injection of 124I-cMAb U36 and 131I-cMAb U36 with a similar iodine/MAb molar ratio provided similar tissue uptake values. Selective tumor uptake was confirmed with positron emission tomography imaging at 24, 48, and 72 h, which detected 15 out of 15 tumors.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

No publication is currently available.

Human Studies

[PubMed]

No publication is currently available.

References

1.
Bosman F.T., Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol. 2003;200(4):423–8. [PubMed: 12845610]
2.
Jiang W.G., Puntis M.C., Hallett M.B. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg. 1994;81(11):1576–90. [PubMed: 7827878]
3.
Albelda S.M. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest. 1993;68(1):4–17. [PubMed: 8423675]
4.
Van Hal N.L., Van Dongen G.A., Rood-Knippels E.M., Van Der Valk P., Snow G.B., Brakenhoff R.H. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer. 1996;68(4):520–7. [PubMed: 8945625]
5.
Heider K.H., Kuthan H., Stehle G., Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004;53(7):567–79. [PubMed: 14762695]
6.
Schrijvers A.H., Quak J.J., Uyterlinde A.M., van Walsum M., Meijer C.J., Snow G.B., van Dongen G.A. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res. 1993;53(18):4383–90. [PubMed: 8364934]
7.
Aogi K., Kitahara K., Urquidi V., Tarin D., Goodison S. Comparison of telomerase and CD44 expression as diagnostic tumor markers in lesions of the thyroid. Clin Cancer Res. 1999;5(10):2790–7. [PubMed: 10537343]
8.
Fortin M.A., Salnikov A.V., Nestor M., Heldin N.E., Rubin K., Lundqvist H. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging. 2007;34(9):1376–87. [PubMed: 17277931]
9.
Verel I., Visser G.W., Vosjan M.J., Finn R., Boellaard R., van Dongen G.A. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2004;31(12):1645–52. [PubMed: 15290121]
PubReader format: click here to try

Views

Search MICAD

Limit my Search:


Related information

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...